Imlifidase not checked

Hansa Biopharma AB

FollowEvery change as it happens, and a Monday email
Stage
in the EU
Next date
Phase 2 trial completes
Trials
4 active
14 in total · 9 in the EU
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“Imlifidase is an immunoglobulin G (IgG)-degrading enzyme of Streptococcus pyogenes that is highly selective towards IgG. The cleavage of IgG generates one F(ab')2- and one homodimeric Fc-fragment and efficiently neutralizes Fc-mediated activities of IgG.”In the company’s words, NCT05937750 on ClinicalTrials.gov
Tested for
Long Term Efficacy and Safety, Kidney Transplantation in Highly Sensitized Patients
Main trialPhase 3
“A prospective, post-authorisation long-term follow-up trial of patients previously treated with imlifidase prior to kidney transplantation, including a non-comparative concurrent reference cohort.”In the company’s words, NCT05937750 on ClinicalTrials.gov
Other names
IdeS · HMED-IdeS · IgG endopeptidase · Idefirix

Other drugs for Kidney Transplantation in Highly Sensitized Patients

All 25 drugs for Kidney Transplantation in Highly Sensitized Patients

Coming up2

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials14

TrialPhaseCompletesWhat it tests
Phase 3Active, not recruiting 30 Apr 2030 A Long-term Follow-up Trial of Patients Previously Treated With Imlifidase Prior to Kidney Transplantation and a Non-comparative Transplanted Patient Group
Phase 2Recruiting 28 Feb 2027 Imlifidase Prior to Kidney Transplant in Highly Sensitised Children
Phase 3Completed 20 Jun 2025 Renal Function in Highly Sensitized Patients 1 Year After Desensitization With Imlifidase Prior to DD Kidney Tx
Phase 3Terminated 23 Jun 2025 A Study With Imlifidase in Anti-GBM Disease
Phase 3Completed 21 Apr 2026 Efficacy and Safety in Imlifidase Desensitized Kidney Tx Patients, Including Two Non-Comparative Reference Cohorts
Phase 2Completed 12 Dec 2017 A Phase II Study to Evaluate the Efficacy of IdeS to Desensitize Transplant Patients With a Positive Crossmatch Test
Phase 2Completed 28 May 2022 An Efficacy and Safety Study of Imlifidase in Treatment of Antibody-Mediated Rejection in Kidney Transplant Patients
Phase 2Terminated 5 Feb 2024 A Study to Investigate DSA Rebound in Patients Treated With Imlifidase Prior to Transplantation
Phase 2Completed 27 Feb 2024 A Study of Imlifidase in Patients With Guillain-Barré Syndrome
Phase 1Terminated 10 Oct 2025 A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) Following Imlifidase Infusion in Participants With Duchenne Muscular Dystrophy (DMD) Determined to Have Pre-existing Antibodies to Recombinant Adeno-Associated Virus Serotype (rAAVrh74)
Phase 2Authorised not given An open-label, phase 2 trial to evaluate the efficacy and safety of a single intravenous administration of GNT0003 (an adeno-associated viral vector expressing the UGT1A1 transgene) following imlifidase pre-treatment in participants aged 16 years and older with severe Crigler-Najjar syndrome requiring daily phototherapy and presenting pre-existing anti-AAV8 antibodies.
Phase 2Ended not given IMLIFIDASE IN LIVING DONOR RENAL TRANSPLANTATION: HIGHLY SENSITIZED RECIPIENTS (LIVEDES STUDY)
Phase 2Authorised not given Imlifidase in ANCA-associated Vasculitis
Phase 2Ended not given lmlifidase treatment tor acute inflammation in AQP4-lgG associated neuromyelitis optica spectrum disorder (DEFEAT NMOSD)
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow Imlifidase

Following is part of Solo: you see every change to Imlifidase the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in